11:50 AM EST, 12/10/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

Cardiff Oncology ( CRDF ) shares rose by more than 50% in recent trading on Tuesday after it said that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.

Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.

Cardiff reported a "deeper tumor response" in those who received a 30 milligram dose compared with those who received 20 milligram.

The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.

The company said it plans to report additional data from the ongoing study in the first half of next year.

Price: 3.63, Change: +1.19, Percent Change: +48.57